DescriptionSources: https://www.medicines.org.uk/emc/medicine/20014Curator's Comment: Description was created based on several sources, including http://www.fkog.uu.se/course/a/biolakt/biolakt-archive/litteratur2011ht/tyrotricin_Marie.pdf and http://www.eurosurveillance.org/images/dynamic/EE/V20N34/art21215.pdf
Sources: https://www.medicines.org.uk/emc/medicine/20014
Curator's Comment: Description was created based on several sources, including http://www.fkog.uu.se/course/a/biolakt/biolakt-archive/litteratur2011ht/tyrotricin_Marie.pdf and http://www.eurosurveillance.org/images/dynamic/EE/V20N34/art21215.pdf
Tyrothricin is a mixture of non-ribosomal peptides produced by Brevibacillus brevis, now known as Aneurinibacillus migulanus, a gram positive aerobic bacteria. The compound mixture shows activity against bacteria, fungi and some viruses. A very interesting feature of AMPs is the fact, that even in vitro it is almost impossible to induce resistances. It is a locally effective antibiotic effective against gram-positive bacteria. It is sometimes combined with benzocaine 5 mg (Tyrozets) to provide relief from sore throats. Recommended for short-term relief of symptoms of oral and throat inflammation. Prevention of infections before/during mouth and throat operations (tooth extractions, gum surgical treatment). Tyrothricin inhibits protein biosynthesis of gram-positive organisms, but is completely ineffective against gram-negative.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Staphylococcus aureus growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/23955154 |
|||
Target ID: Plasmodium falciparum growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/20547797 |
0.05 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Tyrozets Approved UseAs an antibiotic and local analgesic-anaesthetic. For minor mouth and throat irritations; secondary irritation following tonsillectomy and other mouth and throat surgery. Launch Date2008 |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17462586 |
Primary | Unknown Approved UseUnknown |
||
Curative | Tyrosur Powder Approved UseIndications:
Surface wounds with insignificant release of exudate and with superinfection (erosive and ulcerous skin and mucous membrane lesions) caused by pathogenic microorganisms sensitive to Tyrothricin (infected eczema, purulent skin inflammations, burns). |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of malaria parasite blood stages by tyrocidines, membrane-active cyclic peptide antibiotics from Bacillus brevis. | 2007 Jun |
|
Suppressive effects of peptide antibiotics against proliferation and cytokine production in mitogen-activated human peripheral-blood mononuclear cells. | 2011 |
|
Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. | 2014 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/20014
Curator's Comment: Can also be used topically for wounds treatment http://www.ndrugs.com/?s=tyrosur%20powder
Adults : 1 lozenge to be dissolved slowly in the mouth every three hours. Do not exceed 8 lozenges in 24 hours.
Children aged 3 years and older : dosage should be reduced in children. Maximum 6 lozenges in 24 hours. Tyrozets are not recommended for children under the age of three years.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23955154
MIC90 of tyrothricin against methicillin-resistant Staphylococcus aureus isolates was 4 ug/ml
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
6311
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
||
|
WHO-ATC |
S01AA05
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
||
|
WHO-VATC |
QD06AX08
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
||
|
WHO-ATC |
R02AB02
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
||
|
WHO-VATC |
QR02AB02
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
||
|
WHO-VATC |
QS01AA05
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
||
|
WHO-ATC |
D06AX08
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
||
|
NCI_THESAURUS |
C258
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C152789
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
SUB05029MIG
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
m11293
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
1404-88-2
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
DB13503
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
10968
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | RxNorm | ||
|
4739
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
757363
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
TYROTHRICIN
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
1344
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
877376V2XW
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
D014449
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
DTXSID4045846
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL577736
Created by
admin on Sat Dec 16 07:56:05 GMT 2023 , Edited by admin on Sat Dec 16 07:56:05 GMT 2023
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY